|Table of Contents|

Mechanism of TUG1 promoting invasion and metastasis of gastric cancer cells by regulating EZH2

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 08
Page:
1382-1386
Research Field:
Publishing date:

Info

Title:
Mechanism of TUG1 promoting invasion and metastasis of gastric cancer cells by regulating EZH2
Author(s):
LIU Mi1; HE Na1; QIN Jie1; ZHANG Mingxin1; SHI Yingpeng2; WANG Li3
1.Department of Gastroenterology;2.Department of General Medicine,the First Affiliated Hospital of Xi'an Medical University,Shaanxi Xi'an 710032,China;3.Department of Oncology 5,Xi'an International Medical Center Hospital,Shaanxi Xi'an 710100,China.
Keywords:
gastric cancer; TUG1; EZH2; invasion; metastasis
PACS:
R735.2
DOI:
10.3969/j.issn.1672-4992.2024.08.002
Abstract:
Objective:To explore the role and regulatory mechanism of taurine upregulated gene 1 (TUG1) in the invasion and metastasis of gastric cancer cells.Methods:TCGA database analysed TUG1 expression in gastric cancer tissue and its relationship with patient prognosis.TUG1 expression in gastric cancer tissues and cells was detected by qRT-PCR.TUG1 overexpressed knockdown cell line was constructed by cell transfection.Transwell experiment observed the effects of TUG1 overexpression and knockdown on the migration and invasion ability of gastric cancer SGC-7901 cells.Western Blot detected the effects of TUG1 overexpression and knockdown on the activity of the EZH2/STAT3 signaling pathway in gastric cancer SGC-7901 cells.Results:qRT-PCR and TCGA database showed that TUG1 expression was up-regulated in gastric cancer tissues and cells (P＜0.01),and was negatively correlated with prognosis of gastric cancer patients (P＜0.01),but positively correlated with pathological stages and lymphatic metastasis of gastric cancer patients (P＜0.05).Transwell assay showed that upregulation of TUG1 promoted the migration and invasion of gastric cancer cells (P＜0.01).Western Blot result showed that upregulation of TUG1 promoted EZH2 expression and activated STAT3 signaling pathway (P＜0.01).Conclusion:TUG1 promotes the invasion and metastasis of gastric cancer cells by activating EZH2/STAT3 signaling pathway.

References:

［1］ LI H,WANG J,ZHANG L.Construction of a circRNA-related prognostic risk score model for predicting the immune landscape of lung adenocarcinoma［J］.Frontiers in Genetics,2021,12:668311.
[2] SMYTH EC,NILSSON M,GRABSCH HI,et al.Gastric cancer［J］.Lancet,2020,396(10251):635-648.
[3] ADNANE S,MARINO A,LEUCCI E.LncRNAs in human cancers:signal from noise［J］.Trends in Cell Biology,2022,32(7):565-573.
[4] QIU Y,XU M,HUANG S.Long noncoding RNAs:emerging regulators of normal and malignant hematopoiesis［J］.Blood,2021,138(23):2327-2336.
[5] BALIOU S,KYRIAKOPOULOS AM,SPANDIDOS DA,et al.Role of taurine,its haloamines and its lncRNA TUG1 in both inflammation and cancer progression.On the road to therapeutics［J］.International Journal of Oncology,2020,57(3):631-664.
[6] 段学军,宋庆宏,郭俊龙.乳腺癌组织lncRNA TUG1、EZH2表达变化及其临床意义［J］.山东医药,2020,60(22):10-13. DUAN Xuejun,SONG Qinghong,GUO Junlong.Expression of lncRNA TUG1 and EZH2 in breast cancer tissue and its clinical significance［J］.Shandong Pharmaceutical,2020,60(22):10-13.
[7] LIU S,WANG W,YE L,et al.Long noncoding RNA TUG1 promotes proliferation,migration and cisplatin resistance in oral squamous cell carcinoma［J］.Acta Biochimica et Biophysica Sinica,2023,12(21):124-129.
[8] YIN Q,SHN X,XU H,et al.YY1-induced LncRNA-TUG1 elevates YOD1 to promote cell proliferation and inhibit bortezomib sensitivity in multiple myeloma［J］.Leukemia & Lymphoma,2023,64(6):1161-1174.
[9] AZIZIDOOST S,NASROLAHI A,GHAEDRAHMATI F,et al.The pathogenic roles of lncRNA-Taurine upregulated 1 (TUG1) in colorectal cancer［J］.Cancer Cell International,2022,22(1):335.
[10] LI K,NIU H,WANG Y,et al.LncRNA TUG1 contributes to the tumorigenesis of lung adenocarcinoma by regulating miR-138-5p-HIF1A axis［J］.International Journal of Immunopathology and Pharmacology,2021,35:356448439.
[11] LEPRDDA AJ,NIEDDU G,CANNAS C,et al.Molecular and pathobiological insights of bikunin/UTI in cancer［J］.Molecular Biology Reports,2023,50(2):1701-1711.
[12] AJANI JA,LEE J,SANO T,et al.Gastric adenocarcinoma［J］.Nature Reviews.Disease Primers,2017,3:17036.
[13] VAN CUTSEM E,SAGAERT X,TOPAL B,et al.Gastric cancer［J］.Lancet,2016,388(10060):2654-2664.
[14] MAS AM,HUARTE M.Long noncoding RNA signatures as cancer biomarkers［J］.Journal of Clinical Oncology,2023,41(16):3059-3062.
[15] 甘凤娇，胡康，李艳，等.长链非编码RNA在乳腺癌中的研究进展［J］.现代肿瘤医学,2020,28(23):4913-4916. GAN FJ,HU K,LI Y,et al.Research progress of long non-coding RNA in breast cancer［J］.Modern Oncology,2020,28(23):4913-4916.
[16] 何茹，王宇.长链非编码RNA 在宫颈癌中的研究进展［J］.现代肿瘤医学,2020,28(6):1025-1028. HE R,WANG Y.Research progress of long non-coding RNA in cervical cancer［J］.Modern Oncology,2020,28(6):1025-1028.
[17] 朱苗骏，张奉武，吴鸿菲，等.膀胱癌中长链非编码RNA研究进展［J］.现代肿瘤医学,2020,28(21):3820-3826. ZHU MJ,ZHANG FW,WU HF,et al.Advances of long non-coding RNA in bladder cancer［J］.Modern Oncology,2020,28(21):3820-3826.
[18] 金娟,赵晓晓,李丽,等.肿瘤微环境中lncRNA的研究进展［J］.四川大学学报,2023,54(03):491-496. JIN Juan,ZHAO Xiaoxiao,LI Li,et al.Research progress on lncRNA in tumor microenvironment［J］.Journal of Sichuan University,2023,54(03):491-496.
[19] GUO T,TANG XH,GAO XY,et al.A liquid biopsy signature of circulating exosome-derived mRNAs,miRNAs and lncRNAs predict therapeutic efficacy to neoadjuvant chemotherapy in patients with advanced gastric cancer［J］.Molecular Cancer,2022,21(1):216.
[20] LU L,HUANG J,MO J,et al.Exosomal lncRNA TUG1 from cancer-associated fibroblasts promotes liver cancer cell migration,invasion,and glycolysis by regulating the miR-524-5p/SIX1 axis［J］.Cellular & Molecular Biology Letters,2022,27(1):17.
[21]BRAGA EA,FRIDMAN MV,MOSCOVTSEV AA,et al.LncRNAs in ovarian cancer progression,metastasis,and main pathways:ceRNA and alternative mechanisms［J］.International Journal of Molecular Sciences,2020,21(22):327-331.
[22] LU P,JIANG Y,XIA Z.Long noncoding RNA TUG1 decreases bladder cancer chemo-sensitivity toward doxorubicin through elevating KPNA2 expression and activating the PI3K/AKT pathway via adsorbing miR-582-5p［J］.Anti-cancer Drugs,2023,34(1):144-154.
[23] 董程程,武家才.PRC复合物及其亚基EZH2在肿瘤中的研究进展［J］.世界最新医学信息文摘,2018,18(16):71-74. DONG Chengcheng,WU Jiacai.A talented martial artist research progress on PRC complex and its subunit EZH2 in tumors［J］ World's Latest Medical Information Digest,2018,18(16):71-74.
[24] SELLERS WR,LODA M.The EZH2 polycomb transcriptional repressor-a marker or mover of metastatic prostate cancer［J］.Cancer Cell,2002,2(5):349-350.
[25] MIRZAEI S,GHOLAMI MH,HUSHMANDI K,et al.The long and short non-coding RNAs modulating EZH2 signaling in cancer［J］.Journal of Hematology & Oncology,2022,15(1):18.
[26] CAO J,HAN X,QI X,et al.TUG1 promotes osteosarcoma tumorigenesis by upregulating EZH2 expression via miR-144-3p［J］.International Journal of Oncology,2017,51(4):1115-1123.

Memo

Memo:
陕西基础科学（化学、生物学）研究院基础科学研究计划（编号：22JHQ091）
Last Update: 1900-01-01